These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8225392)

  • 1. Mechanism of liposome adjuvanticity: an in vivo approach.
    Fortin A; Thérien HM
    Immunobiology; 1993 Jul; 188(3):316-22. PubMed ID: 8225392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage.
    Shahum E; Thérien HM
    Immunology; 1988 Oct; 65(2):315-7. PubMed ID: 3192275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes as immune adjuvants: T cell dependence.
    Beatty JD; Beatty BG; Paraskevas F; Froese E
    Surgery; 1984 Aug; 96(2):345-51. PubMed ID: 6611598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation.
    Shek PN; Sabiston BH
    Immunology; 1982 Dec; 47(4):627-32. PubMed ID: 6754583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome adjuvanticity: influence of dose and protein:lipid ratio on the humoral response to encapsulated and surface-linked antigen.
    Thérien HM; Shahum E; Fortin A
    Cell Immunol; 1991 Sep; 136(2):402-13. PubMed ID: 1873824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes with differential lipid components exert differential adjuvanticity in antigen-liposome conjugates via differential recognition by macrophages.
    Tanaka Y; Kasai M; Taneichi M; Naito S; Kato H; Mori M; Nishida M; Maekawa N; Yamamura H; Komuro K; Uchida T
    Bioconjug Chem; 2004; 15(1):35-40. PubMed ID: 14733581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation with liposomes: the immune response elicited by liposomes with entrapped dichloromethylene-diphosphonate and surface-associated antigen or hapten.
    Claassen E; Kors N; van Rooijen N
    Immunology; 1987 Apr; 60(4):509-15. PubMed ID: 2953668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
    Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
    Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of physical association between antigen and liposomes in liposomes adjuvanticity.
    Thérien HM; Shahum E
    Immunol Lett; 1989 Oct; 22(4):253-8. PubMed ID: 2628283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increased adjuvanticity of liposomes by the inclusion of phosphatidylserine in immunization with surface-coupled liposomal antigen.
    Mori M; Nishida M; Maekawa N; Yamamura H; Tanaka Y; Kasai M; Taneichi M; Uchida T
    Int Arch Allergy Immunol; 2005 Jan; 136(1):83-9. PubMed ID: 15591816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens.
    Phillips NC; Gagné L; Ivanoff N; Riveau G
    Vaccine; 1996 Jun; 14(9):898-904. PubMed ID: 8843632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response.
    Zigterman GJ; Snippe H; Jansze M; Willers JM
    J Immunol; 1987 Jan; 138(1):220-5. PubMed ID: 3782798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mannose-mediated targeted immunoadjuvant action of liposomes.
    Garcon N; Gregoriadis G; Taylor M; Summerfield J
    Immunology; 1988 Aug; 64(4):743-5. PubMed ID: 3169846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation.
    Shek PN; Yung BY; Stanacev NZ
    Immunology; 1983 May; 49(1):37-44. PubMed ID: 6341213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of systemic and mucosal immune response following nasal administration of liposomes.
    Aramaki Y; Fujii Y; Yachi K; Kikuchi H; Tsuchiya S
    Vaccine; 1994 Oct; 12(13):1241-5. PubMed ID: 7839731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal adjuvanticity: effect of encapsulation and surface-linkage on antibody production and proliferative response.
    Shahum E; Thérien HM
    Int J Immunopharmacol; 1995 Jan; 17(1):9-20. PubMed ID: 7782155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics.
    Davis D; Gregoriadis G
    Immunology; 1987 Jun; 61(2):229-34. PubMed ID: 3596639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen.
    Su D; Van Rooijen N
    Immunology; 1989 Mar; 66(3):466-70. PubMed ID: 2703258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal vaccine: influence of antigen association on the kinetics of the humoral response.
    Thérien HM; Lair D; Shahum E
    Vaccine; 1990 Dec; 8(6):558-62. PubMed ID: 2087877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome.
    Dwivedi V; Vasco A; Vedi S; Dangi A; Arif K; Bhattacharya SM; Owais M
    Vaccine; 2009 Jan; 27(3):473-82. PubMed ID: 18996429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.